QQQ   413.25 (-2.40%)
AAPL   164.99 (-1.23%)
MSFT   398.16 (-1.51%)
META   476.40 (-5.06%)
GOOGL   153.28 (-1.75%)
AMZN   173.54 (-3.17%)
TSLA   146.63 (-2.20%)
NVDA   760.13 (-10.23%)
AMD   146.23 (-5.71%)
NIO   3.79 (-5.25%)
BABA   68.94 (+0.09%)
T   16.49 (+0.98%)
F   12.10 (+0.33%)
MU   106.21 (-5.11%)
GE   148.09 (-3.17%)
CGC   7.97 (+1.79%)
DIS   112.24 (-0.17%)
AMC   3.13 (+7.19%)
PFE   25.96 (+2.24%)
PYPL   61.86 (-0.39%)
XOM   119.93 (+1.19%)
QQQ   413.25 (-2.40%)
AAPL   164.99 (-1.23%)
MSFT   398.16 (-1.51%)
META   476.40 (-5.06%)
GOOGL   153.28 (-1.75%)
AMZN   173.54 (-3.17%)
TSLA   146.63 (-2.20%)
NVDA   760.13 (-10.23%)
AMD   146.23 (-5.71%)
NIO   3.79 (-5.25%)
BABA   68.94 (+0.09%)
T   16.49 (+0.98%)
F   12.10 (+0.33%)
MU   106.21 (-5.11%)
GE   148.09 (-3.17%)
CGC   7.97 (+1.79%)
DIS   112.24 (-0.17%)
AMC   3.13 (+7.19%)
PFE   25.96 (+2.24%)
PYPL   61.86 (-0.39%)
XOM   119.93 (+1.19%)
QQQ   413.25 (-2.40%)
AAPL   164.99 (-1.23%)
MSFT   398.16 (-1.51%)
META   476.40 (-5.06%)
GOOGL   153.28 (-1.75%)
AMZN   173.54 (-3.17%)
TSLA   146.63 (-2.20%)
NVDA   760.13 (-10.23%)
AMD   146.23 (-5.71%)
NIO   3.79 (-5.25%)
BABA   68.94 (+0.09%)
T   16.49 (+0.98%)
F   12.10 (+0.33%)
MU   106.21 (-5.11%)
GE   148.09 (-3.17%)
CGC   7.97 (+1.79%)
DIS   112.24 (-0.17%)
AMC   3.13 (+7.19%)
PFE   25.96 (+2.24%)
PYPL   61.86 (-0.39%)
XOM   119.93 (+1.19%)
QQQ   413.25 (-2.40%)
AAPL   164.99 (-1.23%)
MSFT   398.16 (-1.51%)
META   476.40 (-5.06%)
GOOGL   153.28 (-1.75%)
AMZN   173.54 (-3.17%)
TSLA   146.63 (-2.20%)
NVDA   760.13 (-10.23%)
AMD   146.23 (-5.71%)
NIO   3.79 (-5.25%)
BABA   68.94 (+0.09%)
T   16.49 (+0.98%)
F   12.10 (+0.33%)
MU   106.21 (-5.11%)
GE   148.09 (-3.17%)
CGC   7.97 (+1.79%)
DIS   112.24 (-0.17%)
AMC   3.13 (+7.19%)
PFE   25.96 (+2.24%)
PYPL   61.86 (-0.39%)
XOM   119.93 (+1.19%)
Free Trial
NASDAQ:OREX

Orexigen Therapeutics (OREX) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)
Free OREX Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$0.22
▼
$0.32
50-Day Range
$0.22
▼
$0.22
52-Week Range
$0.17
▼
$3.81
Volume
3.74 million shs
Average Volume
1.16 million shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
OREX stock logo

About Orexigen Therapeutics Stock (NASDAQ:OREX)

Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products primarily in the United States, Europe, and South Korea. It offers Contrave for the treatment of obesity. The company also offers Contrave under the Mysimba brand name. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California. On March 12, 2018, Orexigen Therapeutics, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

OREX Stock News Headlines

April 17, 2024 | businesswire.com
Xeno Biosciences Announces New CEO and Financing
August 27, 2023 | thestreet.com
Orexigen Tanks After-Hours on Obesity Data
April 19, 2024 | Stansberry Research (Ad)
Strange new buyer driving up gold
One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."
August 9, 2023 | finanznachrichten.de
Regulus Therapeutics Inc.: Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates
July 20, 2023 | finance.yahoo.com
Triumvira Immunologics Strengthens its Leadership Team with Three Accomplished Life Sciences Executives
June 20, 2023 | markets.businessinsider.com
MAPLIGHT THERAPEUTICS APPOINTS KRIS HANSON AS GENERAL COUNSEL
May 17, 2023 | marketwatch.com
2023 "Anti-obesity Drugs Market" Key Manufacturers and Regional Outlook 2031
May 16, 2023 | marketwatch.com
Global Anti-obesity Medicine Market Size 2023-2031 Market Dynamics by Absolute Reports | with [86 Pages]
April 19, 2024 | Stansberry Research (Ad)
Strange new buyer driving up gold
One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."
May 5, 2023 | marketwatch.com
The global Weight Loss Therapeutics market Size during the period of 2023 to 2030 is expected grow at CAGR of 11.3%
March 30, 2023 | finance.yahoo.com
Zevra Therapeutics Appoints Biopharma Veteran Wendy Dixon, Ph.D., to Board of Directors
March 30, 2023 | marketwatch.com
Anti-Obesity Drugs Market Factual Overview Research Report 2023-2030
March 29, 2023 | marketwatch.com
Global Anti-Obesity Drugs Market Size 2023 to 2026 Size and Share Survey Report
March 28, 2023 | marketwatch.com
Anti Obesity Drugs Market Size and Forecast till 2028
March 28, 2023 | marketwatch.com
Anti-Obesity Drugs Market New Innovations and Future Expansion 2023-2031
March 21, 2023 | marketwatch.com
Anti-Obesity Drugs (Anti-obesity Medication) Market Share and Forecast till 2028
March 13, 2023 | marketwatch.com
Anti Obesity Drugs Market Continues Aggressive Growth till 2028
March 8, 2023 | marketwatch.com
The Weight Loss Therapeutics Market 2023 is Expected to Udergo Significant Changes Due to New Technologies and Other Industry Related Factors 2030
March 6, 2023 | marketwatch.com
2023-2029 Anti-Obesity Prescription Drugs Market Size and Growth Analysis | Research Report by Absolute Reports
February 23, 2023 | marketwatch.com
Anti-obesity Drugs Market International Business Analysis, Development Outlook and Regional Strategies 2028
December 8, 2022 | marketwatch.com
Weight Loss Therapeutics Market Shows Huge Demand by Shares, Size, Future Trends and Future Scope Including Top Players by 2023-2028
November 18, 2022 | marketwatch.com
Anti-obesity Medicine Market 2023 | Future Growth Segments, Latest Opportunities, Industry Revenue, Size, Share and Leading Players Forecast to 2028
October 13, 2022 | marketwatch.com
Weight Loss Therapeutics Market Size And Opportunities for New Players, Forecast from 2022 To 2028
September 6, 2022 | thestreet.com
Orexigen to Post Obesity Data in Race With Vivus, Arena
September 6, 2022 | marketwatch.com
Obesity Management Market Size 2022 : Technological Advancements in Report & Recent Innovations, Value Chain Analysis Till 2028 | 87 Report Pages
August 22, 2022 | thestreet.com
Orexigen Weight-Loss Pill Shows Surprise Heart-Safety Benefit
August 17, 2022 | marketwatch.com
Anti-obesity Drugs Market Size 2022 Share, Growth By Top Company, Business Opportunity, Region, Application, Driver, Trends and Forecasts By 2028
See More Headlines
Receive OREX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Orexigen Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/13/2017
Today
4/19/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:OREX
CUSIP
68616410
CIK
1382911
Web
www.orexigen.com
Phone
858-875-8600
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
Metaverse Stocks And Why You Can't Ignore Them Cover
Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Michael A. Narachi (Age 59)
    Pres, Chief Exec. Officer & Director
  • Dr. Thomas R. Cannell D.V.M. (Age 56)
    Exec. VP, COO & Pres of Global Commercial Products
  • Mr. Thomas P. Lynch (Age 51)
    Exec. VP, Gen. Counsel, Chief Admin. Officer & Sec.
  • Ms. Monica Forbes (Age 42)
    VP & Acting CFO
  • Mr. Stephen A. Moglia (Age 53)
    Chief Accounting Officer, VP and Controller

Key Competitors

View All Competitors

OREX Stock Analysis - Frequently Asked Questions

How were Orexigen Therapeutics' earnings last quarter?

Orexigen Therapeutics, Inc. (NASDAQ:OREX) issued its quarterly earnings data on Monday, November, 13th. The biopharmaceutical company reported ($1.35) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.13) by $0.78. The biopharmaceutical company had revenue of $18.90 million for the quarter, compared to analysts' expectations of $24.20 million. The firm's revenue for the quarter was up 170.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.12 earnings per share.

What other stocks do shareholders of Orexigen Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Orexigen Therapeutics investors own include Lexicon Pharmaceuticals (LXRX), Arena Pharmaceuticals (ARNA), ImmunoGen (IMGN), MannKind (MNKD), Novavax (NVAX), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Rexahn Pharmaceuticals (REXN), Synergy Pharmaceuticals (SGYP) and Biogen (BIIB).

This page (NASDAQ:OREX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
The “Perfect Storm” for Gold
Gold Safe Exchange
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Biden’s $374B Giveaway Into This Sector
DTI
Your Money is Not Safe
American Alternative
He Is Giving Away Bitcoin
Crypto Swap Profits
The #1 Crypto for 2024
InvestorPlace
SHOCKING Crypto Leak…
Crypto 101 Media
My biggest AI fear
Paradigm Press